A diabetes drug company has filed a new drug application with the Food and Drug Administration (FDA) in America. The new drug, submitted by Lexicon Pharmaceuticals Inc. is designed to treat type 2 diabetes cases.
Following a review by the FDA, the oral drug is going to be put through phase 1 clinical trials to further assess its efficiency. Lexicon are a biopharmaceutical company committed to developing new drug treatments.
The executive vice president and chief scientific office of Lexico, Brian Zambrowicz, reportedly commented: “The mechanism of action of LX4211 specifically blocks reabsorption of glucose by the kidney, which may help to improve glucose control in patients with type 2 diabetes .”

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Top diabetes professor drafts risk assessment document for frontline COVID-19 staff

The health and wellbeing of frontline NHS staff has been prioritised among…

Coronavirus: UK instructed to stay at home this weekend

Health Secretary Matt Hancock has said that staying at home this weekend…

Type 2 diabetes found to be a ‘significant risk factor’ among stroke victims

More evidence has been published which supports that diabetes is a “significant…